Patent 10428142 was granted and assigned to Bluebird Bio on October, 2019 by the United States Patent and Trademark Office.
The present disclosure relates to compositions and methods for using cells having chemically-induced fusion protein complexes to spatially and temporally control immune cell signal initiation and downstream responses for treating disease.